No Items In Cart
The mission of West Regulatory Affairs (RA) is to provide customers with industry leading support for their global regulatory needs. West RA provides a single point of contact to assist with global registration strategies for all West products and processes.
West RA can provide tools to support customers from initial regulatory evaluation of West products through final health authority approval of drug applications—delivering excellent customer service along the way.
Customers looking to transition into a new West product or process need to start with an evaluation of the likely impact of the change to their regulatory files. This is key to building an efficient regulatory submission strategy that will maximize approvability and minimize the time required to achieve approvals.
West RA can provide customers with regulatory assessments to identify potential regulatory risks, suggest mitigation strategies, and provide references to relevant guidances for support. West regulatory assessment documents can provide customers with the tools needed to help build an overall regulatory submission strategy and facilitate the transition.
Regulatory Affairs provides customers with Regulatory Compliance Certificates to verify that West products and processes meet regulatory agency expectations in all major markets.
Examples of compliance certification letters include:
West maintains an extensive portfolio of Drug Master Files (DMFs), Master Access Files (MAFs), 510ks and Canadian Licenses with both the FDA and Health Canada. Some of our DMFs are acknowledged to be the most heavily accessed DMFs at either agency. Upon request, West can provide Letters of Authorization/Access (LOAs) to customers for inclusion in their drug applications.
Each year, West provides over 1800 LOAs to its DMFs, using a convenient online request form. West RA has worked with both FDA and Health Canada to define industry standards for conversion of packaging and process DMFs to electronic format (eCTD). The entire West DMF portfolio has been converted to eCTD, so that files are compliant with FDA and Health Canada requirements for electronic DMFs.
The DMF portfolio includes the following West products and processes:
Global Submission Support Packages are intended to support customers in countries where Drug Master Files (DMFs) and Master Access Files (MAFs) have not been established. They provide customers with the technical information for West products and processes needed for inclusion in their drug applications.
The content of each package is designed to meet Health Authority expectations for pharmaceutical components and delivery systems in drug applications and they are backed by West RA support for any follow-up questions you may receive from reviewing agencies. West currently has or can provide packages for the following products and processes:
When a drug application is being reviewed by a health authority (HA), follow-up questions may be posed and could involve a West component. Regulatory Affairs provides customers with high-quality support for any HA questions regarding West products and processes. West provides the necessary information for inclusion in a response document or can provide responses directly to the relevant agency.
On October 1, 2018, the Food and Drug Administration (FDA) launched the Special 510(k) Program Pilot, which aims to expand on the types of changes eligible for the program to improve the efficiency of 510(k) review.
Medical products are often intended and labeled for use in conjunction with other medical products marketed by different sponsors. In some cases, the medical products are of different types. Typically, the different sponsors collaborate when the two products are to be used together for a new intended use. however, sponsors seek marketing authorization from FDA for a medical product for a new use with the approved, marketed medical product of another sponsor, and the sponsor of the approved, marketed product does not wish to pursue the new use or work with the other product sponsor.
The Drug Price Competition and Patent Term Restoration Act of 1984 (Public Law 98-417) (Hatch-Waxman Amendments) added section 505(b)(2) and 505(j) (Abbreviated New Drug Application (ANDA) to the FD&C Act, which describe abbreviated approval pathways. With the passage of the Hatch-Waxman Amendments, the FD&C Act describes different routes for obtaining approval of two broad categories of drug applications: new drug applications (NDAs) and abbreviated new drug applications
Chinese State Councilor, Wang Yong, delivered an institutional restructuring plan of the State Council at the fourth plenary meeting of the first session of the 13th National People's Congress (NPC) at the Great Hall of the People in Beijing. The draft restructuring plan is intended to make the government better-structured, more efficient, and service-oriented.
Voluntary consensus standards can be a valuable resource for industry and FDA staff. The use of consensus standards can increase predictability, streamline premarket review, provide clearer regulatory expectations, and facilitate market entry for safe and effective medical products.
GDUFA II becomes effective on October 1, 2017, bringing significant changes to the user fee structure. Some of these changes may provide incentives for generic drug manufacturers to pursue manufacturing upgrades that may have previously been prohibitive.
SelfDose™, Westar®, and NovaPure® are registered trademarks or trademarks of West Pharmaceutical Services, Inc., in the United States and other jurisdictions.
SmartDose® is a registered trademark of West Pharma. Services IL, Ltd., a subsidiary of West Pharmaceutical Services, Inc.
Daikyo Crystal Zenith® is a registered trademark of Daikyo Seiko, Ltd.
Daikyo Crystal Zenith® is licensed from Daikyo Seiko, Ltd.